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Abstract 
Degradation is one of the key processes governing the impact of pharmaceuticals in the aquatic 
environment. Most studies on the degradation of pharmaceuticals have focused on soil and sludge with 
fewer exploring persistence in aquatic sediments. Here we investigate the dissipation of six 
pharmaceuticals from different therapeutic classes in a range of sediment types. Dissipation of each 
pharmaceutical was found to follow first-order exponential decay. Half-lives in the sediments ranged 
from 9.5 d (atenolol) to 78.8 d (amitriptyline). Under sterile conditions, the persistence of 
pharmaceuticals was considerably longer. Stepwise multiple linear regression analysis was performed to 
explore the relationships between half-lives of the pharmaceuticals, sediment physicochemical properties 
and the sorption coefficients for the compounds. Sediment clay, silt and organic carbon content and 
microbial activity were the predominant factors related to the degradation rates of diltiazem, cimetidine 
and ranitidine. Regression analysis failed to highlight a key property which may be responsible for 
observed differences in the degradation of the other pharmaceuticals. The present study results suggest 
degradation rate of pharmaceuticals in sediments is determined by different factors and processes and 
does not exclusively depend on a single sediment parameter. 
 
Keywords: Pharmaceuticals, Dissipation, Sediment, Physicochemical properties 
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INTRODUCTION 
Thousands of tonnes of pharmaceuticals are produced and consumed annually for human and veterinary 
medicine (Zuccato et al. 2000; Castiglioni et al. 2005; Sarmah et al. 2006). Generally, following use, 
pharmaceuticals are discharged as either the parent compound or metabolites to the sewerage system 
(Boxall et al. 2012). The incomplete removal of pharmaceuticals in wastewater treatment plants 
(WWTPs) and the relative persistence of these compounds explains their widespread occurrence in the 
natural environment (Kolpin et al. 2002; Benotti and Brownawell 2009; Yan et al. 2013; Chen and Zhou 
2014; Shi et al. 2014). Industrial and hospital emissions, land application of sewage sludge and direct 
disposal are other routes of entry of pharmaceuticals to the environment (Christensen 1998; Daughton and 
Ternes 1999; Kümmerer 2009). With the increasing recognition that pharmaceuticals occur in the 
environment, there is a need for a better understanding of their environmental fate and risks to non- target 
organisms (Daughton and Ternes 1999; Loffler et al. 2005; Mompelat et al. 2009). 
Once pharmaceuticals are introduced into the aquatic environment, their fate and behaviour will be 
determined by processes such as biodegradation, hydrolysis or photodegradation, as well as sorption to 
natural solid matter including suspended solids and bed sediments (Yamamoto et al. 2009; Liang et al. 
2013). Degradation is one of the key processes governing the fate and impacts of organic compounds in 
the environment. Consequently, an assessment of the persistence of a pharmaceutical is required as part of 
the environmental risk assessment process during the marketing authorisation of new pharmaceutical 
active ingredients (EMEA 2006).   
Many studies have explored the degradation of pharmaceuticals in wastewaters (e.g. Quintana et al. 2005; 
Joss et al. 2006), sludge (e.g. &DUEDOODHWDO5DGMHQRYLüHWDO/LDQG=KDQJ and soils 
(Monteiro and Boxall 2009; Xu et al. 2009; Lin et al. 2011). The most important dissipation pathway for 
pharmaceuticals in the environment is microbial degradation (Fang et al. 2012). The rate and degree of 
degradation of pharmaceuticals are affected by the environmental conditions such as pH, temperature, the 
abundance of microorganisms and the presence of biosolids as well as the physicochemical properties of 
the compound such as the degree of dissociation and lipophilicity of the pharmaceutical (Monteiro and 
Boxall 2009). For example, soil texture was found to affect the degradation rates of caffeine, with faster 
degradation being observed in loam and sandy loam soils compared to a silt loam soil (Topp et al. 2006). 
3 
 
Amitriptyline also showed faster dissipation in a loam soil compared to clay and sandy soils (Li et al. 
2013). Benotti and Brownawell (2009) reported variations in degradation rates for 19 pharmaceuticals in 
estuarine and coastal surface water samples and suggested that faster rates of pharmaceutical degradation 
occurred in waters with a greater abundance of total bacteria or the presence of microbial communities 
that are better able to transform these compounds. While data are available on the persistence of 
pharmaceuticals in soils and surface waters, few studies have investigated the behaviour and degradation 
of pharmaceuticals in sediments, even though this compartment is considered as a sink for many 
pharmaceuticals, especially cationic pharmaceuticals (Löffler and Ternes 2003; Loffler et al. 2005; Boxall 
and Ericson 2012).  
The studies that have been done on sediments have focused on anti-inflammatory compounds, antibiotics, 
and lipid regulators. Conkle et al. (2012) focused on the degradation of selected pharmaceuticals under 
aerobic and anaerobic conditions in wetland sediments. Carbamazepine was found to be highly persistent 
in sediment with half-lives between 165-264 d under aerobic conditions and these were increased by 
factors of 1.5-2.5 under anaerobic conditions. Ibuprofen and gemfibrozil showed relatively short half-
lives of around 20 d under aerobic conditions and these increased by factors of 11-34 under anaerobic 
conditions. Ibuprofen showed low half-lives ranging from 1.2 to 2.5 d depending on the flow rate of 
overlying water (Kunkel and Radke 2008). These findings show that hydraulic conditions can drive the 
rate of pharmaceutical degradation in sediment. Thuy and Loan (2014) studied the fate of antibiotics 
(ciprofloxacin, griseofulvin, and rifampicin) in water only and a water-sediment system. The half-lives of 
the antibiotics in the water system (8-20 d) were shorter than in the water-sediment system (23-39 d).     
Although previous studies have reported the degradation of selected pharmaceuticals in sediments, 
limited information is available on the effects of sediment characteristics on the persistence of these 
molecules. A better understanding of the factors that influence degradation rate of pharmaceuticals in 
sediment could help to better inform the environmental risk assessment of pharmaceutical active 
ingredients. Therefore, here we present the findings of a study to characterise the dissipation of six 
human-use pharmaceuticals with different chemical properties and therapeutic usages in ten freshwater 
sediments with a wide range of physicochemical properties.  
4 
 
MATERIALS AND METHODS 
 
Chemicals and solvents 
Analytical grade ( SXULW\) amitriptyline hydrochloride, atenolol, cimetidine, diltiazem 
hydrochloride, mefenamic acid and ranitidine were purchased from Sigma-Aldrich (UK). Chemical 
structures, physicochemical properties and therapeutic uses of the selected pharmaceuticals are given in 
the Supporting Information (Table S1). The study pharmaceuticals were selected based on their usage 
amounts and based on risk-based prioritisation studies, performed by our group, to identify the 
pharmaceuticals of most concern in the environment in the UK (Guo et al. 2016) and Iraq (Al-Khazrajy 
and Boxall 2016a). For example, amitriptyline and mefenamic acid were ranked as high priority 
compounds based on their potential to elicit pharmacological mechanism-related effects in aquatic 
organisms in the UK and Iraq. Atenolol and ranitidine were ranked as high priority based on their 
potential to elicit chronic effects at lower trophic levels in the UK. Solvents (acetonitrile, methanol, 
acetone, ethyl acetate and water) were of high-performance liquid chromatography (HPLC) grade (Fisher 
Scientific). Ammonium hydroxide solution (35%) was purchased from Fisher Scientific. Formic acid (96 
%), 2,3,5-Triphenyl-tetrazolium chloride (TTC) solution, tris (hydroxymethyl) ammoniomethane and 
triphenylformazane (TPF) were obtained from Sigma-Aldrich (UK). Stock solutions of the reference 
FRPSRXQGVZHUHSUHSDUHGLQPHWKDQRODQGVWRUHGDWíƕC until use. 
 
Sediment collection and characterisation  
Eight freshwater sediments, from small rivers and streams in England (located in Yorkshire and 
Leicestershire) and two from Iraq (located in Baghdad and Karbala), were sampled from the top 0-5 cm 
surface layer. Sediments were collected from remote and sparsely urbanized areas which were expected to 
be less affected by pharmaceutical contamination sources (e.g. WWTPs and hospitals). Since the main 
purpose of the current study was to investigate the effect of sediment properties on the degradation of 
pharmaceuticals, sediments were chosen to cover a diverse range of properties (e.g. clay content which 
ranged from 0.35 to 37.25% and organic carbon content (OC) which ranged from 0.98 to 9.90%). 
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Selected physicochemical properties of the sediments are given in Table 1. Sediment samples were 
collected using a pre-cleaned stainless steel spade and placed along with overlying water into 1 L amber 
glass bottles which had been cleaned with acetone, deionized water and then dried. Following collection, 
sediments were transferred to the laboratory, where plant residues and debris were removed manually. 
The wet slurry was then sieved to 2 mm, homogenized and stored at 4oC for less than a month prior to the 
study. For characterisation, the sediments were subjected to granulometric analysis to determine the 
texture using a Malvern laser granulometer (Hydro 2000MU, UK); the OC in the sediments was 
measured according to the ISO10694 protocol using a total carbon content analyzer (Viro Macro 
Elemental (CN) Analyser, Germany). Sediment pH values, in 0.01 M CaCl2, were determined using a 
sediment to solution ratio of 1:5. Cation exchange capacity and exchangeable metals were analysed by 
Forest Research UK following the ISO 11260 & 14254 protocols using a dual view ICP-OES (Thermo 
iCAP 6500 duo). Prior to use of sediments in the degradation study, each sediment type was analysed, 
using the analytical procedures described below, to determine the background levels of the 
pharmaceuticals of interest. For all sediments, background concentrations of the study compounds were 
found to be below the analytical limits of detection. 
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Table 1 Sampling locations and measured properties of the study sediments used in the degradation studies 
Sediment Coordinates  Texture Silt 
% 
Clay 
% 
Sand 
% 
OC 
% 
pH 
CaCl2 
CEC 
(cmol+ 
/kg) 
Bioactivity  
(mg TPF 
/kg 
sediment) 
BTC 54.017012, -
0.881074 
 
Sandy loam  
 
35.48  34.25 62.92 2.83 6.88 13.45 5161.1 
BW 53.982712, -
0.790092 
 
Loam 
 
45.92 4.73 49.35 9.9 8.1 35.58 5521.0 
MIL 53.964920, -
0.719305 
 
Sandy clay  
 
0.88 37.25 61.87 8.02 7.15 37.08 280.2 
GER 53.935850, -
1.054470 
 
Sandy clay 
loam 
1.22 30.97 67.81 5.69 7.1 24.26 2630.8 
HLM 54.242978, -
1.055166 
 
Sandy 
 
10.08 0.12 89.8 0.98 6.65 5.85 825.3 
MOR 54.371324, -
0.965524 
 
Loamy sand 
 
21.05 0.35 78.6 3.52 6.35 11.26 4767.2 
HAB 52.626226, -
0.890155 
 
Loamy sand 
 
26.7 1.12 72.18 1.12 7.45 11.34 404.1 
SKF 52.620847, -
0.905779 
 
Sandy clay 
loam 
0.38 36.52 63.1 7.92 7.02 28.39 4256.0 
BGD 33.361904, 
 44.370943 
 
Silt loam 58.15 2.04 39.81 3.42 7.1 12.99 258.1 
HUS 
 
32.623024, 
44.027632 
Silt loam 71.15 2.91 25.94 3.51 7.3 19.07 428.4 
Sediments from England were collected from Buttercrambe (BTC), Bishop Wilton (BW), Millington (MIL), German beck (GER), Helmsley (HLM) and North 
Yorkshire Moors National Park (MOR), all in North Yorkshire; and Harborough (HAB) and Skeffington (SKF) in Leicestershire. The sediments from Iraq were 
collected from the Tigris River in Baghdad (BGD) and the Alhussainya River (HUS) in Karbala city, TPF=  triphenylformazane. 
 
 
Degradation of pharmaceuticals  
Aerobic degradation studies were performed using sterilised and non-sterilised sediments following the 
method of Ying and Kookana (2003). The persistence of the pharmaceuticals in all sediment types was 
investigated under non-sterile conditions, while four sediments, selected to give a range of extremes of 
sediment characteristics, were used for the sterile studies. In brief, 5 g (dry weight equivalent) of sediment 
were weighed into 40-mL screw capped amber glass vials. The ratio of sediment to solution was 1:1. 
Samples were pre-incubated for 6 d, in the dark. The samples (three replicates) were then spiked with 50 
ȝ/ of the standard solution (containing 20 mg/L of each pharmaceutical) to give a nominal concentration 
of 200 ng/g (dry weight) for each pharmaceutical. Vials were thoroughly shaken for 30 seconds and 
placed in an incubator in the dark at 20 ± 2 oC. Vials were loosely capped to avoid contamination while 
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allowing air exchange. A headspace of about 60% of the vials height was used to provide sufficient 
headspace to ensure aerobic conditions.  
Sterilisation of the sediments was achieved by autoclaving (Prestige medical, UK) sediments at 120 oC 
under 300 kPa for 30 min three times over three consecutive days. To confirm the sterility of the 
autoclaved sediments, the microbial activity of the sediments was tested following the method described 
in the next section. Due to possible water loss during the incubation, sample vials were regularly weighed 
to monitor the water content of the water-sediment system and, if necessary, water content was adjusted 
with HPLC grade water. After each addition, samples were gently shaken (without resuspension of 
sediment fines to avoid the disturbance of sediment-borne microorganisms (Abia et al. 2017)) to ensure 
aerobic conditions. Triplicate subsamples of the sterilised and non-sterilised sediment were withdrawn at 
0, 3, 7, 14, 28, 56 and 90 d following the start of the study and immediately stored in a freezer at ± 22 oC 
until analysis (analysis occurred within one week). 
 
Sediment bioactivity 
The bioactivity of sediments in the degradation experiments was measured by using TTC solution (0.1 g, 
distilled water: 10 ml) to measure dehydrogenase activity in living organisms which is an indicator of 
sediment microbial activity (Monteiro and Boxall 2009).  Subsamples of each sediment type (from day 90 
of the incubation) were incubated with 5 ml (0.5% by weight) of colourless TTC at 30 oC in 0.1M tris 
buffer (tris (hydroxymethyl) ammoniomethane) adjusted to pH 7.6. The colourless TTC is reduced to red 
water-insoluble TPF by the dehydrogenase enzyme in bacteria. After incubation for 24 hours, the TPF 
was extracted with 25 mL of acetone. The samples were then agitated for 1 hour at 250 oscillations min-1 
and centrifuged at 2500 g for 10 min. The absorbance of the supernatant was then measured at 485 nm 
using an Ultraviolet-visible (UV-Vis) spectrophotometer (160 Spectrophotometer, Shimadzu, Japan). The 
absorbance measurements were converted to bioactivity (mg TPF/kg) based on a calibration curve 
developed from a set of TPF standards.  
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Extraction of pharmaceuticals and SPE clean-up 
The study pharmaceuticals were extracted from the test sediments using sonication-assisted extraction 
and extracts were then cleaned-up using solid phase extraction (SPE) according to the procedures 
previously developed by our group (Al-Khazrajy and Boxall, 2017). In brief, frozen samples were thawed 
at room temperature then 10 ml of 2% NH4OH in methanol was added. Samples were then vortexed for 
15 seconds and ultra-sonicated for 15 min. The slurry was then agitated at 250 rpm for 10 minutes. The 
slurry samples were then centrifuged at 4500 rpm for 10 min. The resulting supernatant was filtered 
through a  ȝP Q\ORQ ILOWHU and then decanted into a 500-ml Erlenmeyer flask. The extraction was 
repeated using 2% formic acid in methanol while in a third extraction cycle only 5 ml of methanol was 
used. The supernatants from the three steps were combined and diluted with Milli-Q water (ELGA 
purelab, UK) to produce a total volume of 400 ml (methanol < 5%). 
The aqueous sediment extracts were then adjusted to pH=10 using NH4OH solution prior to a solid phase 
extraction (SPE) clean up step. The SPE was conducted on 6-ml (200 mg) Oasis hydrophilic±lipophilic 
balance (HLB) SPE cartridges (Waters, USA). The preconditioning step was done by passing through 5 
ml of methanol followed by 10 ml of Milli-Q water. The diluted aqueous extract samples were then 
loaded onto the SPE cartridge at a rate of 10-20 ml/min using a vacuum manifold (Supelco VisiprepTM, 
UK) for extraction of 12 samples in parallel, after which the cartridges were rinsed with 10 ml of 5% 
methanol in Milli-Q water and then dried under air for 30 minutes. The cartridges were then eluted with 2 
x 2.5 ml methanol followed by 1.0 ml of 2% NH4OH in methanol. The eluates were dried under a gentle 
nitrogen stream using a concentrator (DB-3A, TECHNE, UK) at 30oC. The dried extract was 
reconstituted into 1.0 ml of methanol: water (20:80) and sonicated for 5 minutes. The reconstituted 
extracts were then stored in a freezer at -22 oC prior to analysis. 
 
Analytical method 
Cleaned-up extracts were analysed by liquid chromatography tandem mass spectrometry (LC-MS/MS) 
using an Applied Biosystems/MDS Sciex API 3000 triple quadrupole mass spectrometer interfaced with a 
Dionex UltiMate® 3000 HPLC. A reversed phase C18 analytical column of 150 mm × 4.6 mm and 5.0 
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ȝPSDUWLFOHVL]H=RUED[(FOLSVH;'%-C18) was used for separation and quantification. A Zorbax Eclipse 
XDB-C18 4.6 mm x 12.5 mm 5.0 ȝP JXDUG FROXPQ ZDV DOVR XVHG The column temperature was 
maintained at 35 °C and the autosampler temperature was set at 4 °C. The injected sample volume was 10 
ȝ/0RELOHSKDVHV$DQG%ZHUH10 mM ammonium acetate/acetic acid buffer (pH 4.8) and acetonitrile 
and the flow rate was 1.0 mL min-1. The gradient elution program was: 90% of mobile phase A for 
equilibration and holding steps for 1 min each, mobile phase B was then increased linearly to 25% over 
10 min, and then rapidly increased to 90 % over 2 min, this composition was held for a further 5 min 
before returning to the initial condition of 10% mobile phase A over 1 min. The column was re-
equilibrated for 6 min at the initial mobile phase composition until 25 min, which was also the total run 
time.  
The tandem mass (MS/MS) analysis was performed using a triple quadrupole mass spectrometer 
equipped with an electrospray ionization (ESI) source. For the MS analysis, standard solutions (1.0 
mg/mL) of each analyte were directly infused along with the mobile phase into the mass spectrometer. 
The positive ion mode was selected on the basis of the presence of a basic functionality in the chemical 
structure of all the pharmaceuticals except mefenamic acid which contains acidic functionality. Even so, 
mefenamic acid exhibited very low limit of detections (LODs) and limit of quantifications (LOQs) so 
there was no need to switch to negative ionization mode. ESI source temperature, capillary and cone 
voltage and flow rate of the desolvation gas were optimized to obtain the highest intensity of precursor 
molecules of the six analytes. The collision gas pressure and collision energy of collision were optimized 
for a maximum response of the fragment ions obtained. Precursor ions and product ions for MS/MS 
detection and their respective collision energies are listed in the supporting information (Table S2) 
together with typical retention times of all target analytes. For MS/MS detection, the instrument was 
operated in Multiple Reactions Monitoring (MRM) mode and identifications were made by comparing 
retention times and substance specific mass spectra. All data were acquired and processed using Analyst 
1.4.2 software. 
The performance of the analytical method (precision, accuracy, LOD and LOQs) are described in Al-
Khazrajy and Boxall (Al-Khazrajy and Boxall 2017). Recoveries for the test chemicals ranged from 
40.1% (ranitidine in BW sediment) to 120.6% (amitriptyline in HAB sediment) and LODs ranged from 
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0.02 (diltiazem) to 2.5 ng/g (mefenamic acid). The relative standard deviations (RSDs) were less than 
16% (see Table S3 in the supporting information). The stability of the study pharmaceuticals during 
storage was also checked. Recoveries from freshly spiked high microbial activity sediment (BTC 
sediment) were compared to equivalent spiked sediments at day 0 that had been stored in a freezer for 90 
days. The recoveries obtained for all pharmaceuticals from the frozen samples were approximately the 
same as those of the freshly spiked samples showing negligible concentration changes (Table S4, 
supporting information).  
 
Data analysis 
The concentrations of pharmaceuticals in the sediment systems were plotted against time of incubation 
using Microsoft Excel 2010 software. The degradation rate constant k (per day) was then estimated by 
fitting a first-order exponential decay model to the data. The time for 50% (DT50) and 90% (DT90) 
dissipation were then estimated.  
 
Statistical analysis  
Statistical analyses (ANOVA and Multiple linear regression (MLR)) were performed using the SPSS 23.0 
statistical software package with the significance level being p<0.05. Prior to the statistical analyses, the 
normality of the data was first evaluated using the Kolmogorov-Smirnov and Shapiro-Wilk methods. All 
variables were found to be normally distributed (p>0.05), except microbial activity and sorption 
coefficients (Kds) for diltiazem and mefenamic acid in the MLR analysis, these were therefore 
normalized using logarithmic transformations. Two way- ANOVA was used for each sediment and 
pharmaceutical to explore differences between concentrations in sediment over time. Stepwise MLR 
analysis was employed to find relationships between degradation rate as the dependent variable and 
combinations of sediment physical-chemical property parameters as the explanatory variables. Model 
adequacy was measured by the squared correlation coefficient (R2), the Fisher criterion (F) and the significance 
level (p).  The general form of the regression equations is described in Equation 1: 
11 
 
Y=b0 + b1X1 + b2X2+ «E5X5 «EnXn                              (1) 
Where Y is the dependent variable representing degradation rate (k), b0 is the intercept, b1. . .bn are 
regression coefficients, and X1±Xn are independent variables referring to the chosen predictors. 
 
RESULTS AND DISCUSSION 
 
Degradation of pharmaceuticals in sediment 
The dissipation of pharmaceutical concentrations in sediments over time is plotted in Figure 1 for the 
non-sterile treatments and Figure 2 for the sterile treatments. Calculated times for half of the compound to 
dissipate (DT50) for sterile and non-sterile treatments are summarised in Table 2. Associated first-order 
degradation rate constants (k) and DT90 values are given in the supporting information in Tables S5 and 
S6. In the non-sterile sediments, no lag phase was observed for the pharmaceuticals, and the degradation 
of pharmaceuticals in the ten sediments was well described by the first-order exponential decay model. 
Relatively poor fits of the dissipation curves were seen for amitriptyline and atenolol in SKF sediment 
and for mefenamic acid in BGD sediment. This may be related to the rapid dissipation during the first 7-
14 d of incubation. There were some marked differences between sediments in their ability to degrade 
different pharmaceuticals even where test sediments had similar characteristics. All six pharmaceuticals 
showed moderate persistence, with DT50 values ranging from 9.5 d (atenolol) to 78.8 d (amitriptyline) 
(Table S5). In general, the degradation half-lives of pharmaceuticals decreased in the order amitriptyline 
> mefenamic acid > diltiazem > cimetidine > ranitidine > atenolol in each individual sediment. The 
dissipation of all six compounds in the four sediments tested under sterilised conditions was also found to 
follow the first-order exponential decay kinetics (Figure 2). Generally, the dissipation of pharmaceuticals 
in the sterile sediments was slower than in the non-sterile systems indicating that biodegradation was 
mainly responsible for the observed dissipation of the study pharmaceuticals. Findings for the individual 
pharmaceuticals are discussed below. 
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Table 2 Calculated half-lives (in days) for the study pharmaceuticals in sediments under non-sterilized (based 
on ten sediments) and sterilised (based on four sediments) conditions 
 
Compound Kinetics Non-sterilised  Sterilised 
Median Min. Max.  Median Min. Max. 
Amitriptyline First order 62.2 44.4 78.8  90.6 76.2 106.6 
Atenolol First order 13.0 9.5 17.4  23.5 20.5 28.8 
Cimetidine First order 27.6 18.5 36.5  42.5 28.2 54.1 
Diltiazem First order 26.7 21.7 35.4  65.2 57.7 78.7 
Mefenamic acid First order 29.3 19.7 35.0  54.7 44.7 60.9 
Ranitidine First order 16.7 10.1 37.5  40.9 35.9 46.8 
 
 
Amitriptyline 
Under non-sterilised conditions, the dissipation of amitriptyline was described well by the first order 
kinetic model and the dissipation was slow compared to the other pharmaceuticals (Figure 1). DT50 
values for the compound ranged from 44.4 to 78.8 d and DT90 values from 147.6 to 261.4 d (supporting 
information Table S5). Significant differences in dissipation were observed across the sediment types (F = 
45.3; P<0.001). Under sterile conditions, half-lives for amitriptyline were higher (supporting information 
Table S5). The half-lives of amitriptyline in BGD and HLM sediment increased from 66.6 to 106.6 d and 
from 78.8 to 105.0 d, respectively, indicating the importance of microorganisms for amitriptyline 
dissipation in these two sediments. While, to the best of our knowledge, no literature data are available on 
the degradation of amitriptyline in sediment, the persistence of the compound has been explored in soil. 
Our half-lives are similar to those reported in soils with different textures where DT50s ranging from 
34.1to 85.3 d were observed (Li et al. 2013). In this study, the dissipation of amitriptyline was suggested 
to result from the formation of non-extractable residues and the degradation of the parent compound to 
nortriptyline (N-desmethyl amitriptyline) and amitriptyline-N-oxide.  
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Atenolol 
Under non-sterilised conditions, atenolol degraded more quickly than the other pharmaceuticals in all 
sediments over time. Dissipation differed significantly between sediment types (F= 4.2 and P<0.001). In 
sterilised treatments, atenolol showed DT50s almost 2-3 times higher than the non-sterile treatments in 
BTC and GER sediments while in BGD and HLM sediment atenolol exhibited only a small increase in 
DT50 values (Table S5). This behaviour suggests that microbial activity may have contributed less to the 
observed dissipation in these sediments and that the observed loss was caused by abiotic processes. The 
observed half-lives for atenolol are greater than the DT50s of between 2.8 and 10.3 d observed by 
.RGHãRYiHWDO>43] in soil. They showed that dissipation of the compound is slow in soil with a higher 
adsorption affinity to atenolol. For many of the compounds, data from other studies suggest that the 
observed dissipation is due to conversion into transformation products. It is important to recognise that 
these transformation products could be more stable than the parent compound and also may pose a risk to 
the environment (Boxall et al. 2004). For atenolol, based on previous work, the observed dissipation may 
be explained by the conversion of the parent molecule to metoprolol acid which comparatively more 
stable in water-sediment systems than atenolol (Svan et al. 2016). 
 
Cimetidine  
Under non-sterile conditions, sediments showed significant differences in their ability to degrade 
cimetidine (F = 9.6; p<0.001) with half-lives ranging from 18.5 d in the HUS sediment to 36.5 d for both 
the MOR and MIL sediments. With the exception of the HUS sediment, cimetidine was found at 
measurable concentrations after 90 d of incubation. Dissipation half times under sterile conditions ranged 
from 28.2 to 54.1 d. The differences in half-lives between sterilised and non-sterilised conditions indicate 
that microorganisms play a role in the dissipation of the molecule. The degradation of the cimetidine in 
solid phase environment has not been studied and reported half-lives are only available for seawater with 
DT50 values ranging from 9.8 to >100 d (Benotti and Brownawell 2009). Degradation of cimetidine in 
aqueous solutions is believed to be via photo oxidation or chlorination (Latch et al. 2003; Buth et al. 
2007).  
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Diltiazem 
Diltiazem showed moderate dissipation in the study sediments with DT50 values of up to 35.4 d being 
obtained. Significant differences in diltiazem dissipation were seen across sediment types (F= 16.0; 
p<0.01). Slow dissipation was observed for diltiazem under sterilised conditions with half-lives ranging 
from 57.7 to 78.7 d. Previously reported half-lives of diltiazem were only found for surface water and 
soil. Benotti and Brownawell, (2009) reported half-lives of diltiazem ranging from 5.5 to 36 d in coastal 
seawater under non-sterile conditions. Wu et al. (2010) reported half-lives for diltiazem of 11- 44 and 14- 
84 d in soils amended with biosolids under aerobic and anaerobic conditions, respectively. In this same 
study, biodegradation and soil texture were reported as the main drivers for the observed dissipation of 
diltiazem.  
 
Mefenamic acid 
Mefenamic acid displayed significant differences in dissipation between the non-sterile sediments (F= 
11.5; p<0.001) with DT50 values ranging from 19.7 to 35.0 d. Unlike in the non-sterilised studies, 
degradation curves for the mefenamic acid were characterized by an initial lag phase (day 0±7) in BTC 
sediment (Figure 2). This would most likely be attributed to adaptation of the microbial population. 
Nevertheless, this lag phase was not observed for the other sediments. Half-lives obtained here agree well 
with those obtained in lake water under different experimental conditions (filtered and non-filtered water, 
sunlight and dark) which ranged from 15.5 to 66.6 d (Araujo et al. 2011) and are to the lower end of the 
range (12.5 to 104 d) found by Yamamoto et al. (2009) in river water sampled from two different urban 
streams. These higher DT50s, previously observed, are probably explained by the lower abundance of 
microbial activity found in surface water in comparison to sediment (Boxall and Ericson 2012).  
 
Ranitidine 
For ranitidine, the maximum half-life observed in non-sterilised treatments was in the HAB sediment 
(37.5 d) and the minimum was 10.1 d in the BW sediment. Significant differences were seen in 
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dissipation across the sediment types (F=5.8 and p<0.001). In sterilised sediments, with the exception of 
the BGD sediment, an initial lag phase in the degradation of ranitidine was observed. Half-lives were 
found to be 1.6 (HLM sediment) to 3.1 (GER sediment) times greater than the non-sterilised treatments 
(supporting information Tables S5, S6) suggesting that biodegradation is the main dissipation mechanism. 
Half-lives ranging from 15 to 100 d for ranitidine have been reported in the literature for seawater 
(Benotti and Brownawell 2009). Ranitidine has also been characterized as not readily biodegradable in a 
Zahn±Wellens inherent biodegradability test (OECD 302 B) (Bergheim et al. 2012).      
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Figure 1 Mean concentration (±S.D.) for pharmaceuticals in the test sediments over time, corrected for day 0 
concentrations, in ten non-sterilised sediments.  
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Figure 2 Mean concentrations (± S.D.) for pharmaceuticals over time, corrected for day 0 concentrations, in 
four sterilised sediments. 
 
 
 
Multiple linear regression analysis 
To better understand the drivers of the observed degradation of pharmaceuticals across sediments, 
relationships between sediment physico-chemical properties, microbial activity and adsorption 
coefficients and degradation rate were explored using multiple linear regression analysis. Lipophilicity of 
the pharmaceutical corrected for the sediment pH (Log Dow) was also included.  Factors such as the OC 
content of the matrix, pH and the level of microbial activity have previously been shown to be important 
parameters determining degradation rates of ionisable compounds (Kah et al. 2007; Xu et al. 2009). The 
adsorption coefficient (Kd) was also included (obtained from Al-Khazrajy and Boxall (2016b) except 
ranitidine) since adsorption may modify the bioavailability of chemicals (Maqueda et al. 2009). Each 
pharmaceutical and sediment was considered individually. The best performing regression models for 
each study compound are shown in Table 3. 
For diltiazem, the first proposed model only included clay % as the main variable describing degradation 
(R2 =0.534; p<0.05). The inclusion of the sediment microbial activity (in log form) in the equation 
improved the fit (R2 = 0.812; p<0.01; Table 3). This suggests that biodegradation is a key process in 
diltiazem dissipation in the tested sediments. The decreasing DT50 of diltiazem with increasing clay 
content is supported by findings of degradation studies of pesticides and pharmaceuticals in other 
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matrices like soil (Xu et al. 2009; Ghafoor et al. 2011; Wu et al. 2012). Silt % (R2= 0.461, p<0.05) was 
selected as the only descriptor for cimetidine. The result observed in the present study for diltiazem and 
cimetidine regarding the involvement of clay and silt in the final regression models is expected since in 
our previous study (Al-Khazrajy and Boxall, 2016b) we found that the sorption affinity of the compounds 
is highly dependent on the log Dow (diltiazem) and OC% and clay% (cimetidine) so the identification of 
these parameters may be a reflection of the fact that they provide information on the bioavailability of the 
molecules to the microbes. For ranitidine the first descriptor chosen by the model was microbial activity 
(R2= 0.631; p<0.01) but when OC% was included, the fit improved (R2 of 0.869; p<0.001). These two 
descriptors are normally found to dominate the degradation of chemicals since microbial activity would 
be higher in an OC rich matrix (Villaverde et al. 2008; Maqueda et al. 2009). None of the sediment 
parameters was identified by the model to clearly describe the degradation of amitriptyline, atenolol and 
mefenamic acid. This may be explained by the fact that degradation of these molecules is driven by 
factors other than those evaluated in this study. For example, factors such as the diversity structure of the 
microbial communities in the different sediments and the chemistry of the sediment pore water could be 
important in determining rates of degradation of the molecules (Boxall and Ericson 2012).  
 
 
 
Table 3 Multiple linear regression equations for predicting degradation rates of the study pharmaceuticals 
based on sediment properties. No relationships were obtained for amitriptyline, atenolol and mefenamic acid 
Compound  Predictor R2 Multiple regression function 
Diltiazem Clay %Microbial activity 
 
0.821** k= 0.01+ 0.00017 (clay %)+ 0.005 log (microbial 
activity) 
Ranitidine Microbial activity 
OC % 
 
0.869 ** k= 0.16 log (microbial activity)+ 0.02 (OC%)- 0.021 
Cimetidine Silt % 0.461 * k= 0.022 + 0.00015 (silt %) 
** p < 0.01, *p<0.05. 
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CONCLUSION 
The study focused on primary degradation of the study compounds. Results showed some marked 
differences between the sediments in their ability to degrade different pharmaceuticals. The most 
persistent compound amongst the pharmaceuticals studied was amitriptyline while atenolol was found to 
degrade the most quickly. The present study also investigated the effects of a range of variables on the 
dissipation of targeted pharmaceuticals in environmental freshwater sediment. Results indicated that some 
pharmaceuticals are amenable to microbial degradation while for others, the dissipation was probably 
driven by abiotic processes or the formation of nonextractable residues. MLR demonstrated that 
degradation of pharmaceuticals in sediment is a very complex process and cannot be explained by a 
single mechanism due to different interactions between different processes that influence the breakdown 
of pharmaceuticals. Pharmaceuticals with similar structures may also behave differently as shown in the 
current study for the two antihistamines. Microbial degradation appeared to dominate the dissipation of 
diltiazem and ranitidine while abiotic breakdown was found to explain the breakdown of cimetidine. The 
factors governing the other pharmaceuticals in sediments were unclear. In the future, we recommend that 
work is done using a wider range of well characterized pharmaceuticals and sediments. Such work could 
lead to the development of new models that would allow the prediction of degradation of pharmaceuticals 
at high spatial resolutions. These models will be invaluable for better characterizing the environmental 
fate of pharmaceuticals in natural systems. 
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